GSK, ITeos Lung Cancer Therapy Outperforms Jemperli in Mid-stage Trial
Moderna's Faces 'Material Headwinds' on RSV, COVID, RBC Says
Analyst Issues Sell Rating for GlaxoSmithKline Amid Market Share and Litigation Concerns
Blenrep (Belantamab Mafodotin) in Combination Receives Breakthrough Therapy Designation in China for Treatment of Relapsed/refractory Multiple Myeloma
GSK's HSV Vaccine Study Fails to Meet Primary Efficacy Goal
Fulcrum Crashes as GSK-partnered Lead Program Fails
Express News | Earlier Today, GSK Announced Headline Results Of A Phase 2 Trial For Its MRNA Seasonal Influenza Vaccine Program, Demonstrating A And B Strain Immune Responses Relative To Standard Of Care In Both Younger And Older Adults
GSK's MRNA Flu Vaccine Advances to Late-Stage Clinical Development After Positive Trial Results
GSK Reaches Another Settlement in Zantac Litigation
Express News | GSK Confirms It Has Reached A Confidential Settlement With Mr. Isaac Dixon, Resolving The Prostate Cancer Case Filed In Illinois State Court; GSK Does Not Admit Any Liability In This Settlement. The Case Will Now Be Dismissed
GSK Halts Herpes Simplex Virus Vaccine Development, Clears Path For Other Contenders Like Moderna, BioNTech
Express News | Earlier Today GSK's Phase 1/2 Proof-Of-Concept Study Of GSK3943104 Did Not Meet The Study's Primary Efficacy Objective, Hence It Will Not Progress To Phase 3 Studies
GSK's HPV Vaccine Misses Main Goal in Early-to-Mid Stage Study
Berenberg Bank Maintains GlaxoSmithKline(GSK.US) With Buy Rating, Maintains Target Price $46
GSK's Herpes Vaccine Candidate Setback Unlikely to Shake Share Price -- Market Talk
GSK Says Herpes Vaccine Candidate Study Failed to Meet Primary Objective
Statement: Zantac (Ranitidine) Litigation – Dixon Case
GSK Provides Update on Phase I/II Therapeutic Herpes Simplex Virus (HSV) Vaccine Trial
Adult Vaccine Market Forecasts Report and Competitive Landscape 2024-2032 Featuring GlaxoSmithKline, AstraZeneca, Sanofi Pasteur, Pfizer, and CSL
GSK Shingles Vaccine Now Available In Malaysia